novo nordisk glp 1 drug promotes new GLP-1 receptor agonist to fight diabetes, obesity < Pharma < Article Novo's Wegovy becomes first GLP-1

doi: 10.1007/s11154-021-09669-7 8 GriecoMGiorgiAGentileMCdErmeMMoranoSMarasBet al

Therefore, it is necessary to consider the possibility that these changes affected the results

These allow GLP-1 receptor agonists manufacturers to run production that is consistent and predictable

In addition, GLP-1 RAs are particularly effective in reducing HbA1c, which is especially relevant as HbA1c levels 6.5% have been shown to be associated with increased incidence of microvascular complications [69] while it is challenging to achieve HbA1c levels 30 ml/min/1.73 m 2 [2], with a GLP-1 RA as the preferred agent if additional therapy is needed for glycemic control

A 20% relative risk reduction in MACE, including myocardial infarction, stroke, and cardiovascular death and a 30% relative risk reduction in hospitalizations for HF (58)

Gorgojo-Martnez J, Mezquita-Raya P, Carretero-Gmez J, Castro A, Cebrin-Cuenca A, Torres-Snchez A, et al